Published Research and Presentations

TRIALS IN PROGRESS -P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for individuals aged 11-45 years with intermediate and poor-risk metastatic germ cell tumours

P3BEP

ASCO 2024

29/01/2024

B Mak, B Tran, AJ Martin, FD Pashankar, D Mazhar, RA Huddart, M Wheater, E Walpole, DR Feldman, E Dunwoodie, NJ Lawrence, AJ Birtle, D Wyld, AG Stevanovic, JM Balagtas, MR Stockler, PS Grimison, Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Radiographic progression without PSA progression in metastatic hormone-sensitive prostate cancer (mHSPC): a retrospective analysis from the ENZAMET trial (ANZUP 1304)

ENZAMET

ASCO 2024

29/01/2024

Ian D. Davis, Andrew James Martin, Robert R. Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David W. Pook, Francis Parnis, Scott A. North, Gavin M. Marx, John McCaffrey, Raymond S. McDermott, Andrisha -Jade Inderjeeth, Lisa Horvath, Mark Frydenberg, Simon Chowdhury, Kim N. Chi, Martin R. Stockler, Christopher J. Sweeney

Baseline disease characteristics of participants enrolled on ENZARAD (ANZUP 1303) and DASL-HiCaP(ANZUP 1801) trials of highly effective androgen receptor antagonists in high-risk localized or locally advanced prostate cancer (PCa)

DASL-HiCaP

ASCO 2024

29/01/2024

Tamim Niazi, Paul L. Nguyen, Scott Williams, Martin R. Stockler, Andrew J. Martin, Lisa Horvath, Hayley Thomas, Danka S. Zebic, Felicia Roncolato, Tee Lim, Chakiath Jose, Jarad Martin, Hans T. Chung, Annie Ebacher, Scott C. Morgan, Simon Hughes, Sean M. McBride, Paul J. Kelly, Ian D. Davis, Christopher J. Sweeney, The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

CLIMATE: Assessing the Clinical utility of miR-371a-3p as a marker of residual disease in Clinical Stage 1 Testicular Germ Cell Tumour following orchidectomy (ANZUP 1906)

CLIMATE

2023 ASCO Annual Meeting

02/06/2023

Ciara Conduit, Jeremy Lewin, Aaron R. Hansen, Peter Grimison, James Lynam, Andrew Weickhardt, Phillip Parente, David Campbell, Wei Hong, Gavin Marx, Orlaith Heron, Ben Namdarian, Anna Kuchel, Margaret McJannett, Thomas Cusick, Antoinette Fontela, Sophie O’Haire, Kristina Zlatic, Ian D. Davis, and Ben Tran, on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group.

P3 BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs) (TPS5102)

P3BEP

2023 ASCO Annual Meeting

02/06/2023

DS Zebic, B Tran, AJ Martin, FD Pashankar, D Mazhar, RA Huddart, M Wheater, ET Walpole, E Dunwoodie, DR Feldman, AJ Birtle, D Wyld, NJ Lawrence, MR Stockler, PS Grimison on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group

Adding mitomycin (MM) to Bacillus Calmette-Guérin (BCG) as adjuvant intravesical therapy for high-risk, non muscle-invasive urothelial bladder cancer (NMIBC) (BCGMM; ANZUP 1301)

BCG+MM

2023 ASCO Annual Meeting

02/06/2023

D Hayne, MR Stockler, AJ Martin, S McCombie, DS Zebic, PA Bastick, EK Beardsley, M Frydenberg, W Green, J Grummet, C Hawks, J Ischia, A Mitterdorfer, M Patel, M Roberts, S Sengupta, RK Srivastav, AD Redfern, ID Davis, on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)

E: A randomized non-comparative phase II trial of biomarker driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (ANZUP 1903)

GUIDE

2023 ASCO Annual Meeting

02/06/2023

Ciara Conduit, Blossom Mak, Wenjia Qu, Juliana Di lulio, Ronan Burder, Matthias Bressel, Thomas Cusick, Haryana M Dhillon, Richard De Abreu Lourenço, Craig Underhill, Javier Torres, Megan Crumbaker, Florian Honeyball, Anthony Linton, Sanjeev Sewak, Ray Allen1, Ian D Davis, Susan J Clark, Lisa G Horvath, *, Kate L Mahon, * on behalf of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)